Evolent Health faces volatility with missed targets and 2024 guidance cuts. Click here for a full investment analysis of EVH ...

Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Evolent Health (EVH – Research Report). The ...

Healthcare solutions company Evolent Health (NYSE:EVH) in Q4 CY2024, but sales rose 16.3% year on year to $646.5 million.

Welcome to the Evolent earnings conference call for the fourth quarter and year ended December 31, 2024. All participants ...

Q4 2024 Management View CEO Seth Blackley noted Evolent Health achieved $2.55 billion in revenue for 2024, reflecting a 30% growth over the prior year, and $160.5 million in adjusted EBITDA at the low ...

Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting results tomorrow after market close. Here’s what to ...

Evolent Health, Inc. (NYSE:EVH), a healthcare technology and services company with a market capitalization of $1.12 billion, finds itself at a critical juncture as it navigates challenges in its ...

NYSE EVH opened at $10.44 on Friday. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The stock has a 50-day moving average of $10.75 and a 200 day moving average of $18. ...

Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. These figures are ...

Evolent Health, Inc. ( NYSE: EVH) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - ...